Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07059377 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Semaglutide for Smoking Cessation in Patients With Diabetes

Study acronym: GLP1-SC
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 4 months later Jul 2026 → Dec 2026
See other at-risk trials from Ottawa Heart Institute Research Corporation

Record History

  1. Primary completion pushed from Jul 2026 to Dec 2026v5
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Sep 2025 to Feb 13, 2026
    • Study sites: 0 to 1
    v4
  3. Start date: Jul 2025 to Sep 2025v3
  4. Re-verified, no change to tracked fieldsv2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
To assess the feasibility of conducting a randomized controlled trial (RCT) to determine the effectiveness of semaglutide as an adjunct to combination NRT in supporting smoking cessation for patients with diabetes.
Trial Details
NCT Number NCT07059377
Lead Sponsor Ottawa Heart Institute Research Corporation
Conditions
(from sponsor)		 Diabetes Mellitus, Type 2, Nicotine Addiction, Tobacco Dependence
Related terms Diabetes Mellitus, Type 2, Tobacco Use Disorder
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov